PDS Biotechnology Corporation - Common Stock (PDSB)
Competitors to PDS Biotechnology Corporation - Common Stock (PDSB)
Inovio Pharmaceuticals, Inc. INO +1.49%
Inovio Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of DNA medicines, particularly focusing on immunotherapies for cancer and infectious diseases. Like PDS Biotechnology, Inovio is developing innovative immunotherapy treatments designed to enhance the body's immune response. Both companies are engaged in advancing therapeutic candidates that target similar pathways and patient populations, thus competing for research grants, partnerships, and investor interest. Their competition is intensified by the similar technological approaches they employ, though Inovio has a more established clinical pipeline and partnerships, which may give it a competitive edge.
Mylan N.V. (now part of Viatris Inc.) VTRS -0.63%
Mylan, now part of Viatris, was a well-recognized generic and specialty pharmaceutical company that offered a broad range of medications, including oncology products. Mylan competes with PDS Biotechnology primarily in providing accessible oncology therapies. While they are not direct competitors in the immunotherapy space, Mylan's established market presence and diverse product portfolio, along with its global distribution network, allow it to challenge PDS Biotechnology in the broader cancer treatment market. However, Mylan's size and established brands provide a more traditional competitive advantage over PDS, which is focused on innovative therapies.
Novavax, Inc. NVAX +1.30%
Novavax, Inc. is also in the realm of biotechnology with a focus on developing innovative vaccines for infectious diseases, including its notable COVID-19 vaccine candidate. While Novavax's primary focus is on vaccine development, its experience in immunotherapies overlaps with PDS Biotechnology's interests. Both companies seek to leverage immune responses for therapeutic purposes, creating a competitive landscape, particularly in attracting investments and collaborations. However, Novavax's extensive experience in clinical trials and regulatory approvals gives it a significant advantage in terms of credibility and market presence.